Orticumab is under clinical development by Abcentra and currently in Phase II for Acute Coronary Syndrome. According to GlobalData, Phase II drugs for Acute Coronary Syndrome have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Orticumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Orticumab overview
Orticumab is under development for the treatment of acute coronary syndrome and coronary inflammation. The drug candidate is administered intravenously. It is developed based on F.I.R.S.T Technology.
Orticumab was also under development for the treatment of atherosclerosis in patients with rheumatoid arthritis, secondary prevention of cardiovascular events (acute coronary artery disease) and aortic valve stenosis.
Abcentra overview
Abcentra is developing orticumab for treating coronary artery disease. The company is headquartered in Torrance, California, the US.
For a complete picture of Orticumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
